Once-weekly alendronate: Two year subgroup efficacy analyses in postmenopausal women with osteoporosis.

被引：0
|
作者：
Bone, H
Felsenberg, D
Greenwald, M
Schnitzer, T
Kaur, A
Cudny, M
Peverly, C
Orloff, J
Santora, A
机构：
[1] Michigan Bone & Mineral Clin PC, Detroit, MI USA
[2] Free Univ Berlin Klinikum, Berlin, Germany
[3] Desert Med Advances, Palm Desert, CA USA
[4] Northwestern Univ, Chicago, IL 60611 USA
[5] Merck Res Labs, Rahway, NJ USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2001年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S526 / S526
页数：1
相关论文
共 50 条
  • [41] The effectiveness of alendronate (70 mg weekly) in women with postmenopausal osteoporosis
    Martchenkova, L. A.
    Dreval, A. V.
    Kryukova, I. V.
    Tishenina, R. S.
    Milov, N. M.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S44 - S44
  • [42] Treatment with once-weekly alendronate oral jelly compared with once-weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open-label, prospective, observational study
    Okimoto, Nobukazu
    Uemura, Yukari
    Yoshioka, Toru
    Arita, Shinobu
    Tsurukami, Hiroshi
    Otomo, Hajime
    Nishida, Satoshi
    Ogawa, Takayuki
    Hirao, Ken
    Ikeda, Satoshi
    Matsumoto, Hidehiro
    Toten, Yoriko
    Katae, Yuji
    Okazaki, Yuichi
    Nakagawa, Tsuyoshi
    Sakai, Akinori
    HEALTH SCIENCE REPORTS, 2019, 2 (01)
  • [43] COMPARING DAILY STRONTIUM RANELATE WITH ONCE WEEKLY ALENDRONATE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    Galesanu, Corina
    Lisnic, Natalia
    Florescu, Alexandru
    Loghin, Andra Iulia
    Aancute, Adrian
    Zaharia, Valentin
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S88 - S88
  • [44] Comparison of raloxifene and alendronate on markers of cardiovascular health in postmenopausal women with osteoporosis.
    Adachi, JD
    Reginster, J
    Qu, Y
    Siddhanti, S
    Keech, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S379 - S379
  • [45] Patient compliance and preference of Alendronate's once weekly administration in comparison with Alendronate's daily administration in Osteoporosis in postmenopausal women
    Babiolakis, D
    Stamatiadou, A
    Andronis, C
    Piskontaki, I
    Xristogiannis, F
    Kousta, E
    Spanoudis, D
    Athanasiou, I
    Basilakis, P
    Georgiadis, AE
    BONE, 2004, 34 : S75 - S75
  • [46] Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
    Sugimoto, T.
    Nakamura, T.
    Nakamura, Y.
    Isogai, Y.
    Shiraki, M.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (09) : 2323 - 2324
  • [47] Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
    Emkey, RD
    Reid, I
    Mulloy, AL
    Correa-Rotter, R
    Favus, M
    Bone, H
    Gupta, J
    LaMotta, A
    Santora, AC
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S32 - S32
  • [48] Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women
    Emkey, RD
    Reid, I
    Mulloy, AL
    Correa-Rotter, R
    Favus, M
    Bone, H
    Gupta, J
    La Motta, A
    Santora, AC
    BONE, 2003, 32 (05) : S206 - S206
  • [49] Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis
    Harris, ST
    Watts, NB
    Li, Z
    Chines, AA
    Hanley, DA
    Brown, JP
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (05) : 757 - 764
  • [50] Comparison of changes in bone mineral density and bone turnover marker with alendronate once-weekly and bi-weekly in postmenopausal Korean women
    Oh, H.
    Joe, I.
    Yu, B.
    Kim, K.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S133 - S133
12345